StockData
Radiopharm Theranostics Ltd logo

Radiopharm Theranostics Ltd (RADX) income statement

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30
$0.69+0.01 (+2.10%)

Close on Nov 18, 2026Market cap $8.09MP/E –Yield –

Radiopharm Theranostics Ltd income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin
9.5%
Operating margin
-2051.5%
Net margin
–
Return on equity, FY2026
–

Financial strength

Current ratio
1.16
Debt to equity
–
Debt to assets
–
Cash to current liabilities
21.9%

Valuation

P/E ratio
–
Price to sales
2.92
Price to book
–
Dividend yield
–

See a number that looks wrong?